Thursday, November 26, 2015 3:56:08 PM
~ BMSN = SUMMARY OF HEMAXELLERATE PROGRESS~(UPDATED NOV~2015)
BMSN partially Owns RGBP!
RGBP Owns HEMAXELLERATE!!
Jan 24, 2013 - Pre-clinical proof of concept and plan to file IND.
http://ih.advfn.com/p.php?pid=nmona&article=55986712
Feb 5, 2013 - Announcement that IND was filed.
http://ih.advfn.com/p.php?pid=nmona&article=56150687
Mar 18, 2013 - Regen receives IND# from FDA.
http://ih.advfn.com/p.php?pid=nmona&article=56788567
Apr 4, 2013 - FDA will send a letter outlining items which must be addressed prior to initiating clinical trials.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
Jun 6, 2013 - Regen responds to FDA questions (including new data).
http://ih.advfn.com/p.php?pid=nmona&article=57897013
Jul 31, 2013 - Regen in second round of discussion with FDA on a new set of FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=58628844
Sept 26, 2013 - Agreement for pre-clinical animal trials with WP Min to address FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=59372541
Oct 31, 2013 - Cook General Biotechnology to continue producing clinical grade HemaXellerate for pre-clinial and clinical studies.
http://ih.advfn.com/p.php?pid=nmona&article=59847939
Dec 11, 2013 - Update on WP Min work regarding pre-clinical animal studies
http://ih.advfn.com/p.php?pid=nmona&article=60352616
May 12, 2014 - FDA accepted the clinical protocol and the product manufacturing information; clarification on animal safety studies was requested.
http://ih.advfn.com/p.php?pid=nmona&article=62167863
Sept 10, 2014 - Regen to submit additional safety data from a GLP-certified lab prior to initiating clinical trials.
http://www.marketwired.com/press-release/regen-biopharma-provides-update-on-hemaxellerate-ind-progress-after-conference-call-otcbb-rgbp-1945965.htm
Oct 6, 2014 - Experimental protocol submitted to FDA regarding proposed pre-clinical experiments; follow-up from previous PR.
http://www.marketwired.com/press-release/regen-biopharma-submits-experimental-protocol-fda-hemaxellerate-aplastic-anemia-trial-otcbb-rgbp-1954889.htm
Oct 14, 2014 - Dr. Amit Patel Joins Scientific Advisory Board, has experience in over 17 FDA trials; will assist Regen with HemaXellerate and dCellVax.
http://www.marketwired.com/press-release/cell-therapy-expert-dr-amit-patel-joins-regen-biopharma-inc-scientific-advisory-board-otcbb-rgbp-1957807.htm
Jan 14, 2015 - Progress update for 2015; FDA is reviewing protocols for HemaXellerate GLP safety study.
http://www.marketwired.com/press-release/regen-biopharma-inc-provides-update-on-companys-progress-areas-specialization-2015-otcbb-rgbp-1982809.htm
Mar 17, 2015 - Regen received final comments and authorization from the FDA to proceed with the GLP safety study; clinical trial anticipated to begin once GLP data is reviewed by the FDA.
http://www.marketwired.com/press-release/regen-receives-green-light-from-fda-proceed-with-glp-safety-study-support-its-hemaxellerate-otcbb-rgbp-2001028.htm
Apr 7, 2015 - Thomas Ichim will present a poster entitled "HEMAXELLERATE I™, AUTOLOGOUS ADIPOSE STROMAL VASCULAR FRACTION CELLS, FOR SEVERE APLASTIC ANEMIA" at the 13th International Symposium on Myelodysplastic Syndromes. RGBP also has two other presentations scheduled for this symposium.
http://www.marketwired.com/press-release/regen-biopharma-inc-present-multiple-presentations-13th-international-symposium-on-myelodysplastic-otcbb-rgbp-2007259.htm
Apr 13, 2015 - Selection process of potential GLP labs (for HemaXellerate safety study) narrowed down to two candidates.
http://www.marketwired.com/press-release/regen-biopharma-narrows-selection-cro-candidates-hemaxellerate-glp-safety-studies-requested-2008917.htm
Apr 22, 2015 - Regen selects Charles River Laboratories to carry out the GLP safety study for HemaXellerate. Expected to be last phase of experimentation before clinical trials can begin.
http://www.marketwired.com/press-release/regen-biopharma-inc-engages-charles-river-laboratories-initiate-fda-requested-study-otcbb-rgbp-2012279.htm
Sept 25, 2015 - Regen receives audited draft report from Charles River showing no adverse effects in 10X dose of HemaXellerate in animal safety study. Expected 10-patient clinical trial forthcoming.
http://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-positive-results-from-glp-safety-study-for-hemaxellerate-529494211.html
Nov 17, 2015 - Regen submits response (including GLP preclinical toxicology data from CRL) to the FDA. Expecting FDA clearance to begin HemaXellerate clinical trial.
http://www.prnewswire.com/news-releases/regen-biopharma-inc-submits-response-to-fda-questions-on-hemaxellerate-investigational-new-drug-application-550996231.html
** All dates listed above refer to the date of the linked PR **
$ RGBP $
BMSN partially Owns RGBP!
RGBP Owns HEMAXELLERATE!!
Jan 24, 2013 - Pre-clinical proof of concept and plan to file IND.
http://ih.advfn.com/p.php?pid=nmona&article=55986712
Feb 5, 2013 - Announcement that IND was filed.
http://ih.advfn.com/p.php?pid=nmona&article=56150687
Mar 18, 2013 - Regen receives IND# from FDA.
http://ih.advfn.com/p.php?pid=nmona&article=56788567
Apr 4, 2013 - FDA will send a letter outlining items which must be addressed prior to initiating clinical trials.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
Jun 6, 2013 - Regen responds to FDA questions (including new data).
http://ih.advfn.com/p.php?pid=nmona&article=57897013
Jul 31, 2013 - Regen in second round of discussion with FDA on a new set of FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=58628844
Sept 26, 2013 - Agreement for pre-clinical animal trials with WP Min to address FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=59372541
Oct 31, 2013 - Cook General Biotechnology to continue producing clinical grade HemaXellerate for pre-clinial and clinical studies.
http://ih.advfn.com/p.php?pid=nmona&article=59847939
Dec 11, 2013 - Update on WP Min work regarding pre-clinical animal studies
http://ih.advfn.com/p.php?pid=nmona&article=60352616
May 12, 2014 - FDA accepted the clinical protocol and the product manufacturing information; clarification on animal safety studies was requested.
http://ih.advfn.com/p.php?pid=nmona&article=62167863
Sept 10, 2014 - Regen to submit additional safety data from a GLP-certified lab prior to initiating clinical trials.
http://www.marketwired.com/press-release/regen-biopharma-provides-update-on-hemaxellerate-ind-progress-after-conference-call-otcbb-rgbp-1945965.htm
Oct 6, 2014 - Experimental protocol submitted to FDA regarding proposed pre-clinical experiments; follow-up from previous PR.
http://www.marketwired.com/press-release/regen-biopharma-submits-experimental-protocol-fda-hemaxellerate-aplastic-anemia-trial-otcbb-rgbp-1954889.htm
Oct 14, 2014 - Dr. Amit Patel Joins Scientific Advisory Board, has experience in over 17 FDA trials; will assist Regen with HemaXellerate and dCellVax.
http://www.marketwired.com/press-release/cell-therapy-expert-dr-amit-patel-joins-regen-biopharma-inc-scientific-advisory-board-otcbb-rgbp-1957807.htm
Jan 14, 2015 - Progress update for 2015; FDA is reviewing protocols for HemaXellerate GLP safety study.
http://www.marketwired.com/press-release/regen-biopharma-inc-provides-update-on-companys-progress-areas-specialization-2015-otcbb-rgbp-1982809.htm
Mar 17, 2015 - Regen received final comments and authorization from the FDA to proceed with the GLP safety study; clinical trial anticipated to begin once GLP data is reviewed by the FDA.
http://www.marketwired.com/press-release/regen-receives-green-light-from-fda-proceed-with-glp-safety-study-support-its-hemaxellerate-otcbb-rgbp-2001028.htm
Apr 7, 2015 - Thomas Ichim will present a poster entitled "HEMAXELLERATE I™, AUTOLOGOUS ADIPOSE STROMAL VASCULAR FRACTION CELLS, FOR SEVERE APLASTIC ANEMIA" at the 13th International Symposium on Myelodysplastic Syndromes. RGBP also has two other presentations scheduled for this symposium.
http://www.marketwired.com/press-release/regen-biopharma-inc-present-multiple-presentations-13th-international-symposium-on-myelodysplastic-otcbb-rgbp-2007259.htm
Apr 13, 2015 - Selection process of potential GLP labs (for HemaXellerate safety study) narrowed down to two candidates.
http://www.marketwired.com/press-release/regen-biopharma-narrows-selection-cro-candidates-hemaxellerate-glp-safety-studies-requested-2008917.htm
Apr 22, 2015 - Regen selects Charles River Laboratories to carry out the GLP safety study for HemaXellerate. Expected to be last phase of experimentation before clinical trials can begin.
http://www.marketwired.com/press-release/regen-biopharma-inc-engages-charles-river-laboratories-initiate-fda-requested-study-otcbb-rgbp-2012279.htm
Sept 25, 2015 - Regen receives audited draft report from Charles River showing no adverse effects in 10X dose of HemaXellerate in animal safety study. Expected 10-patient clinical trial forthcoming.
http://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-positive-results-from-glp-safety-study-for-hemaxellerate-529494211.html
Nov 17, 2015 - Regen submits response (including GLP preclinical toxicology data from CRL) to the FDA. Expecting FDA clearance to begin HemaXellerate clinical trial.
http://www.prnewswire.com/news-releases/regen-biopharma-inc-submits-response-to-fda-questions-on-hemaxellerate-investigational-new-drug-application-550996231.html
** All dates listed above refer to the date of the linked PR **
$ RGBP $
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.